TherapeuticsMD, Inc. — Director's Dealing 2018

Sep 28, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2018-09-25

Reporting Person: Milligan John C.K. IV (Director, President/Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-25	Common Stock	M	125000	$0.1018	Acquired	1597419	Direct
2018-09-25	Common Stock	S	125000	$6.778	Disposed	1472419	Direct
2018-09-26	Common Stock	M	125000	$0.1018	Acquired	1597419	Direct
2018-09-26	Common Stock	S	125000	$6.776	Disposed	1472419	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-25	Non-Qualified Stock Option (right to buy)	$0.1018	M	125000	Disposed	2019-01-01	Common Stock (125000)	Direct
2018-09-26	Non-Qualified Stock Option (right to buy)	$0.1018	M	125000	Disposed	2019-01-01	Common Stock (125000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	434814	Indirect
Common Stock	3557373	Indirect

Footnotes

F1: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.61 to $6.885, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.7 to $6.88, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: By the Milligan Irrevocable Nonexempt Trust - 2014. These securities are held in a trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F5: By John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended.